Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor. (2022)

First Author: Miller DC
Attributed to:  Discovery of ERK5 inhibitors for biomarker-driven clinical evaluation in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1021/acs.jmedchem.1c01756

PubMed Identifier: 35468293

Publication URI: http://europepmc.org/abstract/MED/35468293

Type: Journal Article/Review

Volume: 65

Parent Publication: Journal of medicinal chemistry

Issue: 9

ISSN: 0022-2623